Have a feature idea you'd love to see implemented?
Let us know!
ARWR Arrowhead Pharmaceuticals Inc
Price (delayed)
$19.45
Market cap
$2.42B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5
Enterprise value
$2.83B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
Highlights
The quick ratio has soared by 72% YoY and by 46% from the previous quarter
The net income has dropped by 192% year-on-year and by 11% since the previous quarter
ARWR's EPS has plunged by 160% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of ARWR
Market
Valuations
Earnings
Shares outstanding
124.43M
Market cap
$2.42B
Enterprise value
$2.83B
Price to book (P/B)
13.04
Price to sales (P/S)
656.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
796.43
Revenue
$3.55M
Gross profit
$3.55M
Net income
-$599.49M
EBIT
-$569.91M
EBITDA
-$551.31M
Free cash flow
-$604.32M
Per share
Balance sheet
Liquidity
EPS
-$5
EPS diluted
-$5
Free cash flow per share
-$5.05
Book value per share
$1.49
Revenue per share
$0.03
TBVPS
$9.44
Total assets
$1.14B
Total liabilities
$948.74M
Debt
$510.55M
Equity
$185.44M
Working capital
$592.3M
Debt to equity
2.75
Current ratio
6.74
Quick ratio
6.6
Net debt/EBITDA
-0.74
Margins
Efficiency
Dividend
EBITDA margin
-15,525.6%
Gross margin
100%
Net margin
-16,882.4%
Operating margin
-16,927.1%
Return on assets
-66.5%
Return on equity
-206.7%
Return on invested capital
-60.8%
Return on capital employed
-55%
Return on sales
-16,049.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARWR stock price
How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-0.26%
1 week
-10.98%
1 month
3.96%
1 year
-30.11%
YTD
-36.44%
QTD
0.41%
Financial performance
How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$601.08M
Net income
-$599.49M
Gross margin
100%
Net margin
-16,882.4%
The operating income has dropped by 193% year-on-year and by 10% since the previous quarter
The net income has dropped by 192% year-on-year and by 11% since the previous quarter
The company's revenue has shrunk by 99% YoY and by 82% QoQ
The gross profit has shrunk by 99% YoY and by 82% QoQ
Growth
What is Arrowhead Pharmaceuticals's growth rate over time
Valuation
What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
13.04
P/S
656.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
796.43
ARWR's EPS has plunged by 160% YoY and by 7% from the previous quarter
The equity has contracted by 44% from the previous quarter and by 32% YoY
The price to book (P/B) is 9% higher than the 5-year quarterly average of 12.0 and 3.5% higher than the last 4 quarters average of 12.6
The price to sales (P/S) is 181% more than the last 4 quarters average of 233.8
The company's revenue has shrunk by 99% YoY and by 82% QoQ
Efficiency
How efficient is Arrowhead Pharmaceuticals business performance
The company's return on assets has shrunk by 170% YoY
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 125% YoY but it has increased by 13% QoQ
The company's return on equity fell by 20% QoQ
Dividends
What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARWR.
Financial health
How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 20% higher than its total liabilities
The total liabilities has surged by 98% year-on-year and by 74% since the previous quarter
The quick ratio has soared by 72% YoY and by 46% from the previous quarter
Arrowhead Pharmaceuticals's debt is 175% higher than its equity
The equity has contracted by 44% from the previous quarter and by 32% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.